- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05336773
Ulcerative Colitis Mayo Score With Artificial Intelligence
April 14, 2022 updated by: Yanling Wei, Third Military Medical University
Research on Artificial Intelligence-based Mayo Score Recognition System for Disease Activity Degree of Ulcerative Colitis Under Digestive Endoscopy
This project will use deep learning to classify colonoscopy images of different severity of ulcerative colitis, so as to assist clinicians in the accurate diagnosis of ulcerative colitis.
Study Overview
Status
Not yet recruiting
Conditions
Detailed Description
In this project, artificial intelligence was used to colonoscopic images of patients with ulcerative colitis with different disease activity levels and classify them according to the evaluation standard Mayo score to assist endoscopists in identifying disease activity levels of patients with ulcerative colitis during colonoscopy.
It can help clinical endoscopists to accurately identify, and the visualization technology of artificial intelligence category response map can comprehensively display the areas with high importance for deep network classification results, and visualize the experimental lesion sites, thus effectively verifying the reliability and interpretability of deep network.
This study can provide strong support for accurate identification of disease activity in clinical ulcerative colitis, effectively reduce the workload of clinicians, and provide a convenient, effective and practical clinical teaching tool.
Study Type
Observational
Enrollment (Anticipated)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yanling Wei, professor
- Phone Number: +8615310354666
- Email: lingzi016@tmmu.edu.cn
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 400042
- Third Military Medical University
-
Contact:
- Yanling Wei, Professor
- Phone Number: 15310354666
- Email: lingzi016@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 72 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The images were retrieved from the endoscopy database of Army Medical Center of PLA and obtained from the colonoscopy of patients with ulcerative colitis who met the inclusion criteria.
The data images were used to establish and verify the model of ai-assisted recognition system.
Description
Inclusion Criteria:
- Subjects were 18-72 years old, male and female;
- Clinical diagnosis of ulcerative colitis;
- The subjects underwent colonoscopy and the colonoscopy report was complete.
Exclusion Criteria:
- Subjects are younger than 18 years old or older than 72 years old;
- Subjects underwent colectomy, ileostomy, colostomy, ileostomy, or other intestinal resection;
- subjects with ambiguous diagnosis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The accuracy of deep learning model in the training and validation datasets assessment of Mayo score in ulcerative colitis patients.
Time Frame: Through study completion, an average of 1 year.
|
In the training and validation datasets, we plotted the AUC (area under curve) for Mayo 0, Mayo 1, Mayo 2, and Mayo 3 to evaluate our model objectively.
|
Through study completion, an average of 1 year.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The accuracy and time efficiency of endoscopists assessment of Mayo score in ulcerative colitis patients.
Time Frame: Through study completion, an average of 1 year.
|
The dataets were randomly assigned to endoscopists.
All endoscopists were trained in diagnostic studies, finished both clinical and specific endoscopic training, and were not involved in the enrollment and labeling of the patients and images.
During the comparison test, all data were randomized and deidentified beforehand.
The average time spent by 10 endoscopists in diagnosing the test dataset in the deep learning model and the number of correct cases were analyzed.
|
Through study completion, an average of 1 year.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Yanling Wei, Professor, Third Military Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
April 1, 2022
Primary Completion (ANTICIPATED)
December 1, 2022
Study Completion (ANTICIPATED)
June 1, 2023
Study Registration Dates
First Submitted
February 27, 2022
First Submitted That Met QC Criteria
April 14, 2022
First Posted (ACTUAL)
April 20, 2022
Study Record Updates
Last Update Posted (ACTUAL)
April 20, 2022
Last Update Submitted That Met QC Criteria
April 14, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TMMU-DP--002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Odyssey TherapeuticsRecruitingUlcerative Colitis (UC) | UC - Ulcerative ColitisAustralia, Austria, Jordan, Poland, Ukraine, New Zealand, Canada, Czechia, Lithuania, Moldova
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker Cochin; MRSU 938 - Research Center of Saint...Not yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Palatin Technologies, IncActive, not recruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Eli Lilly and CompanyRecruitingUlcerative Colitis, Active Severe | Ulcerative Colitis (UC) | Ulcerative Colitis, Active ModerateUnited States, China, Croatia, France, India, Japan, Israel, Taiwan, Brazil, Serbia, Greece, Hungary, Argentina, Italy, Poland, Czechia, Colombia, Lithuania, Latvia, Ukraine, South Africa, Portugal, Mexico, Canada, Slovakia, Turkey (Türkiye) and more
-
Merck Sharp & Dohme LLCRecruitingUlcerative Colitis | Colitis UlcerativeUnited States
-
InventisBio Co., LtdRecruitingModerately to Severely Active Ulcerative Colitis | UC - Ulcerative ColitisChina
-
Dr Abdurrahman Yurtaslan Ankara Oncology Training...CompletedDisease Activity | Ulcerative Colitis Flare | Remission of Ulcerative ColitisTurkey